Magnesium glycinate is a form of magnesium bound to the amino acid glycine. It is often used as a supplement due to its high bioavailability and gentle effect on the digestive system. Some anecdotal evidence suggests that magnesium glycinate may synergize when combined with ketamine therapy, potentially enhancing the antidepressant effects or reducing side effects.

One possible mechanism for this synergistic effect is that magnesium acts as a natural NMDA (N-methyl-D-aspartate) receptor antagonist, similar to ketamine. NMDA receptor antagonism is thought to contribute to ketamine’s rapid antidepressant effects. Therefore, magnesium glycinate supplementation may theoretically enhance ketamine’s therapeutic efficacy.

However, it is essential to note that the evidence supporting the use of magnesium glycinate in combination with therapeutic ketamine for mental health is limited. Further research is needed to determine this combination’s potential benefits and risks.

Please note that the above sources provide information on the potential synergistic effects of magnesium and NMDA receptor antagonism but do not specifically address the combination of magnesium glycinate and therapeutic ketamine for mental health. Clinical studies investigating this specific combination are currently lacking.

Murck, H. (2002). Magnesium and Affective Disorders. Nutritional Neuroscience, 5(6), 375-389.

Chiechio, S., & Copani, A. (2019). The NMDAR Antagonist and Redox Modulator KH176 Rescues the Activity of the Mitochondrial Respiratory Chain in a Cellular Model of Oxidative Stress. Antioxidants (Basel, Switzerland), 8(11), 510.

Notify of

Inline Feedbacks
View all comments